About the study
AERIFY-4 was a Phase 3 extension study for adults with COPD who had completed one of the earlier itepekimab COPD studies. It evaluated the long-term safety and tolerability of itepekimab, an investigational antibody that blocks interleukin-33 (IL-33), given every two or four weeks, and continued to track flare-ups and lung function.
Who took part
The study enrolled people who:
- Completed the treatment period of an earlier itepekimab COPD study (EFC16750 or EFC16819)
- Were 40 to 85 years old
Status at Veritas
This study has been completed. It is no longer enrolling, and it is listed here as part of Veritas Clinical Research's track record as a research site.
Learn more
The full study record, including all eligibility criteria and outcome measures, is on ClinicalTrials.gov (NCT06208306).